# US 2015/0148296 A1 · Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148296 A1
- Document ID: US20150148296A1
- Status: Published application
- Kind: A1
- Application number: 14/404,222
- Filed: 2013-05-17
- Published: 2015-05-28
- Earliest claimed: 2012-05-31
- Assignees: Asahi Kasei Pharma Corporation; Kinki University
- Applicants: Kinki University; Asahi Kasei Pharma Corporation
- Inventors: Atsufumi Kawabata; Hideaki Suzuki
- Web page: https://patentgrep.com/patent/US20150148296A1

## CPC

- A61K 38/366: {Thrombomodulin}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7455: {Thrombomodulin}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.

## Claims

### Claim 1

A method for prophylactic and/or therapeutic treatment of a chemotherapy-induced peripheral neuropathic pain, which comprises the step of administering thrombomodulin to a mammal.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the thrombomodulin is a soluble thrombomodulin.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein the thrombomodulin is a human thrombomodulin.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathic pain is one or more kinds of symptoms selected from numbness of extremities, pain of extremities, reduction of deep tendon reflection, reduction of muscle force, allodynia, hyperalgesia, and motor dysfunction.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathic pain is allodynia.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the allodynia is mechanical allodynia.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the anticancer agent in chemotherapy consists of one or more kinds of agents selected from the group consisting of a taxane drugs and a platinum preparation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the anticancer agent in chemotherapy is paclitaxel.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the anticancer agent in chemotherapy is administered according to FOLFOX therapy or FOLFIRI therapy.

### Claim 10 (depends on 1)

The method according to claim 1, wherein thrombomodulin is intermittently administered.

### Claim 11 (depends on 1)

The method according to claim 1, which is administered to a cancer patient suffering from one or more kinds of cancers selected from the group consisting of ovarian cancer, non-small cell cancer, breast cancer, gastric cancer, endometrial cancer, head and neck cancer, esophageal carcinoma, leukemia, malignant lymphoma, pediatric tumor, multiple myeloma, malignant astrocytoma, neuroglioma, trophoblastic disease, germ cell tumor, lung cancer, orchioncus, vesical cancer, renal pelvic tumor, urethrophyma, prostate cancer, uterine cervix carcinoma, neuroblastoma, small cell lung cancer, osteosarcoma, malignant pleural mesothelioma, malignant osteoncus, and colon cancer.

### Claim 12

A method for prophylactic and/or therapeutic treatment of a chemotherapy-induced peripheral neuropathic pain, which is administered together with the anticancer agent, and comprises thrombomodulin as an active ingredient.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the thrombomodulin is a peptide obtainable from a transformed cell prepared by transfecting a host cell with a DNA coding for the amino acid sequence of (i-1) or (i-2) mentioned below, and the peptide is a peptide having the thrombomodulin activities;
(i-1) the amino acid sequence of SEQ ID NO: 9 or 11, or
(i-2) the amino acid sequence of (i-1) mentioned above, further including substitution, deletion or addition of one or more amino acid residues.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the thrombomodulin is a peptide containing the amino acid sequence of (i-1) or (i-2) mentioned below, and the peptide is a peptide having the thrombomodulin activities;
(i-1) the amino acid sequence of the positions 19 to 516 in the amino acid sequence of SEQ ID NO: 9 or 11, or
(i-2) the amino acid sequence of (i-1) mentioned above, further including substitution, deletion or addition of one or more amino acid residues.

### Claim at position 15

15-16. (canceled)
